Circassia to Receive $10.5 Million After US Approval of Beyond Air's LungFit Product; Shares Rise
29 Junho 2022 - 7:59AM
Dow Jones News
By Kyle Morris
Shares in Circassia Group PLC rose Wednesday after it said that
it is entitled to receive payments of $10.5 million following
Beyond Air Inc.'s confirmation that it had received approval from
the Food and Drug Administration for its LungFit PH device for the
treatment of hypoxic respiratory failure in newborn children.
Shares at 1027 GMT were up 3.00 pence, or 9.1%, at 35.90
pence.
The U.K. medical-device company said, thanks to an agreement
with Beyond Air, it is entitled to receive $2.5 million within 60
days of approval, $3.5 million within 60 days of the first
anniversary of approval, and $4.5 million within 60 days of the
second anniversary of approval. Furthermore, Circassia is entitled
to a royalty of 5% of net sales of the device, starting on the
second anniversary of approval, up to a maximum of $6 million, it
said.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
June 29, 2022 06:44 ET (10:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Circassia (LSE:CIR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Circassia (LSE:CIR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Circassia Group Plc da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Circassia Group Plc